The CEO detailed "a 35% increase from our previous plan" in total transmission investments, with $19 billion allocated, and noted expectations for company-wide investment to translate into 10% rate ...
Eli Lilly trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential. Click here to read why LLY is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results